Member Info for Retireby40

Yes they didn’t for delta but this from what the scientists say is so much worse and likely to evade current monoclonal antibody LFTs -

https://twitter.com/drericding/status/1464119235655970819?s=21

If this new variant becomes dominant and with so many mutations one would think most countries will ask for tests to be revalidated which would be good for us.

Didn’t Avacta produce a test for Zika not a vaccine?

When the share price is struggling and well down on discounted placing investors want to see their BoD buy shares. Today’s RNS is a shocker. They reduced the amount to mask over the fact they wanted cash rather than shares. Appalling and transparent as the reaction tells us. Am getting more frustrated with Gerry who’s more an MD of a small private firm than CEO of a PLC. Given the great financial position any rise in the next 12 months will take the ****.

I’m also of the view that the market wants solid news and that it would have preferred for the directors to take a reduced number of shares than reduced cash. Not a good look at all.

We know the EU has our outstanding validation and user data sets so it is a matter of time. Our affimers are less likely to be evaded versus normal antibodies and ours are cheaper and quicker to make, if necessary.

New variant info below which could make LFTs less effective.
Some of the mutations are associated with resistance to neutralizing antibodies (and therapeutic monoclonal antibodies from vaccines), more efficient cell entry and the evasion of innate immunity, which could enhance transmissibility, as well as increased infectivity, De Oliveira told a health ministry media briefing on Thursday

Ding with MWG revenues (nearly 2 months) we didn’t beat 2020 guidance by anything.

I know we’re in early stages but the CEO needs to start delivery campaigns that produce revenue rather than multiple partnerships that deliver squat.

The question is with TP targeting £150m+ market cap will DVRG want to behave like one and have a more grown up annual report with divisional revenue break down, KPIs and so on? If we ‘only’ hit £10m given we know we have had 2 orders of £5.8m for MWG I am worried labskin is no longer growing. Anyway, hopefully we can have some transparency and get among the road to a more mature group and lay out business model, strategy, KPIs properly.

In the meantime I’m looking forward to an update. We had one on Dec 1 last year but that was ahead of a presentation so maybe we have to wait to early Jan for a TU.

That said really hope news on China drops ASAP.

Chesh we guided £4m snd then with acquisition of MWG in Nov went to £4.4m. So with the entire year of MWG it would be nearer to £6m today so growth of circa 70%.

Anyway, let’s see what then next update brings. I would prefer licensing deals or OEMs unless we take 50% up front for the orders I’m not sure how we’d fund.

Agreed. We need the CR deal to regain share price momentum and sentiment (rather than FY21 revenue). Clearly these deals are complicated but it was initially meant to be signed months ago and operational in Sept then we had early Q4 (Oct) so I just hope it sighs this Q to head into 2022 on a more positive footing.

Given the £5.3m in MWG orders to be readied this year I would hope to be nearer to £13m than £10m. Given we did £4.4m last year (say £400k from MWG) adding to the above MWG orders there is very little growth so I expect to be higher as labskin would have grown. Let’s see.

That was a little odd. They usually have one on first 2 weeks of Jan to publish unaudited figure. I guess they might have one soon to say £10m on track. Question is how much cash on balance sheet. Hopefully deals come in soon.

Hey Nd, do you the difference between its and it’s?

I don’t get why anyone thinks a different name for the same LFT and an accompanying brochure is material. It isn’t. In actual fact ABDX saying they have substantial orders is more worthy. Get a grip people!

HUA news this month i reckon and I’m sure the above will accompany that material news.

They are at an exhibition and are marketing the product before authorisation granted to sell.

ND getting the newbies spike thread back. Ha!

Anyway, I am not expecting an RNS tomo unless HUA is granted. The lay-user study although impressive isn’t material. I expect the HUA lands soon though!

What is market sensitive?! It’s a user study which is immaterial until HUA is granted. We didn’t RNS the study once Medusa completed it.

Not material until they have the green light to sell. We know Medusa has exclusive B to C rights so a brochure and different brand name to the same isn’t material.

Held up well. Yep, the idea!

I’m around 40k shares away from my target. Waiting to sell elsewhere and will then leave 500k for the ride.

The issue I have is the co has more partners than campaigns! I’m sure that’ll change and hopefully the next Tier 1 signs up certainly before Q2. I expected it this year but I’m sure once the second drops the others will follow quickly.